# Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk

Source: https://onco.cc/trials/nct02945033/  
OnCo record `nct02945033` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in colorectal cancer, run by University Hospital, Rouen, active but no longer recruiting.

## Summary

Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk is a phase 3, randomised interventional study registered as NCT02945033 by University Hospital, Rouen, with a registry enrolment figure of 264 participants, started 2018-07-12 and due to reach its primary completion in 2028-07. Interventions recorded: aspirin intake; placebo intake; Surgical resection of colonic adenocarcinoma stage III or II high risk; Molecular analysis of exon 9 and 20 of PI3K; blood intake. Conditions listed: Colorectal Cancer. Primary outcome: Number of patient with local or distant recurrence or second colorectal cancer or death from any cause, whichever occurred first. Colorectal eligibility wording from the registry: "* Colonic adenocarcinoma stage III". Sites: France. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Also known as: ASPIK French
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT02945033
- Phase: 3
- Setting: French Prospective Randomised Double Blind Study, on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation
- Sponsor: University Hospital, Rouen
- Enrolled: 264

## Sources

- ClinicalTrials.gov NCT02945033: https://clinicaltrials.gov/study/NCT02945033

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct02945033.json